journal
MENU ▼
Read by QxMD icon Read
search

Endocrine-related Cancer

journal
https://www.readbyqxmd.com/read/28442560/obesity-and-menopause-modify-the-epigenomic-profile-of-breast-cancer
#1
Ana B Crujeiras, Angel Díaz-Lagares, Olafur A Stefansson, Manuel Macias, Juan Sandoval, Juan Cueva, Rafael López-López, Sebastian Moran, Jon G Jonasson, Laufey Tryggvadottir, Elinborg Olafsdottir, Francisco J Tinahones, Marcos C Carreira, Felipe F Casanueva, Manel Esteller
Obesity is a high risk factor for breast cancer. This relationship could be marked by a specific methylome. The current work was aimed to explore the impact of obesity and menopausal status on variation in breast cancer methylomes. Data from Infinium 450K array-based methylomes of 64 breast tumor were coupled with information on BMI and menopausal status. Additionally, DNA methylation results were validated in 18 non-tumor and 81 tumor breast samples. Breast tumors arising in either pre- or postmenopausal women stratified by BMI or menopausal status alone were not associated with a specific DNA methylation pattern...
April 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28442559/impact-of-27-hydroxylase-cyp27a1-and-27-hydroxycholesterol-in-breast-cancer
#2
Siker Kimbung, Chingyi Chang, Pär-Ola Bendahl, Laura Dubois, Will J Thompson, Donald P McDonnell, Signe Borgquist
The impact of systemic 27-hydroxycholesterol (27HC) and intra-tumoral CYP27A1 expression on pathobiology and clinical response to statins in breast cancer needs clarification. 27HC is an oxysterol produced from cholesterol by the monooxygenase CYP27A1, which regulates intracellular cholesterol homeostasis. 27HC also acts as an endogenous selective estrogen receptor (ER) modulator capable of increasing breast cancer growth and metastasis. 27HC levels can be modulated by statins or direct inhibition of CYP27A1, thereby attenuating its pro-tumorigenic activities...
April 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28438782/incidence-and-prevalence-of-multiple-endocrine-neoplasia-2b-in-denmark-a-nationwide-study
#3
Jes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, Mette Madsen, Kirstine Stochholm, Per Løgstrup Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Sten Schytte, Henrik Baymler Pedersen, Christoffer Holst Hahn, Jens Bentzen, Mette Gaustadnes, Torben Falck Ørntoft, Thomas van Overeem Hansen, Finn Cilius Nielsen, Kim Brixen, Anja Lisbeth Frederiksen, Christian Godballe
Extract: Multiple endocrine neoplasia 2B (MEN2B) is an autosomal dominant inherited cancer syndrome associating medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), ganglioneuromatosis of the aerodigestive tract and facial, ophthalmologic and skeletal abnormalities. MEN2B is caused by the M918T and A883F mutation of the REarranged during Transfection (RET) proto-oncogene in approximately 95% and <5% of cases, respectively. Only very few other mutations have been reported to cause MEN2B. In approximately 75% of MEN2B patients, mutations occur as de novo (Wells, et al...
April 24, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28432084/topoisomerase2%C3%AE-and-thymidylate-synthase-expression-in-adrenocortical-cancer
#4
Elisa Roca, Alfredo Berruti, Silviu Sbiera, Ida Rapa, Ester Oneda, Paola Sperone, Cristina L Ronchi, Laura Ferrari, Salvatore Grisanti, Antonina Germano, Barbara Zaggia, Giorgio Scagliotti, Martin Fassnacht, Marco Volante, Massimo Terzolo, Mauro Papotti
Topoisomerase II alpha (TOP2A) and Thymidylate Synthase (TS) are known prognostic parameters in several tumors and also predictors of efficacy of anthracyclines, topoisomerase inhibitors and fluoropirimidines, respectively. Expression of TOP2A and TS mRNA was assessed in 98 patients with adrenocortical carcinoma (ACC) and protein expression was assessed by immunohistochemistry in a subset of 39 tumors. Ninety-two patients were radically resected for stage II-III disease and 38 of them received adjuvant mitotane...
April 21, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28428267/association-of-nf%C3%AE%C2%BAb-polymorphisms-with-clinical-outcome-of-non-medullary-thyroid-carcinoma
#5
Theo S Plantinga, Mirela Petrulea, Marije Oosting, Leo Joosten, Doina Piciu, Jan Wa Smit, Romana T Netea-Maier, Carmen Georgescu
The NF-κB inflammatory pathway plays a major role in cancer development and clinical progression. Activation of NF-κB signaling is promoted by NFKB1 and inhibited by NFKBIA. The present study aimed to determine the relevance of NFKB1 rs4648068 and NFKBIA rs2233406 genetic variants for non-medullary thyroid cancer (NMTC) susceptibility, progression and clinical outcome. This case-control and cohort study consists of a Romanian discovery cohort (157 patients, 258 controls) and a Dutch validation cohort (138 patients, 188 controls)...
April 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28420659/very-low-expression-of-pd-l1-in-medullary-thyroid-carcinoma
#6
Massimo Bongiovanni, Caterina Rebecchini, Chiara Saglietti, Jean-Luc Bulliard, Laura Marino, Laurence De Leval, Gerasimos P Sykiotis
Monoclonal antibodies that inhibit the interaction between PD1 and PD-L1 are approved for clinical use in several cancer types, and they are also in clinical trials for additional indications, including thyroid carcinomas. A few papers have reported on PD-L1 expression in thyroid carcinomas, including a recent large study by Ahn et al. in Endocrine-Related Cancer using tissue microarrays on differentiated and anaplastic thyroid carcinoma. However, the expression of PD-L1 in medullary thyroid carcinoma (MTC) has not been reported so far, even though ongoing clinical studies aim to test the effectiveness of checkpoint inhibitors in this rare histotype as well...
April 18, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28400403/molecular-imaging-in-the-investigation-of-hypoglycaemic-syndromes-and-their-management
#7
David A Pattison, Rodney J Hicks
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors - somatostatin receptors (SSTR) and glucagon-like peptide-1 receptor (GLP-1R) - the Amine Precursor Uptake and Decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28400402/molecular-targeted-therapies-in-adrenal-pituitary-and-parathyroid-malignancies
#8
Anna Angelousi, Georgios K Dimitriadis, Gn Zografos, Svenja Nölting, Gregory A Kaltsas, Ashley B Grossman
Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary and parathyroid glands...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28389504/circulating-tumor-cells-and-mirna-as-prognostic-markers-in-neuroendocrine-neoplasms
#9
Maria Chiara Zatelli, Erika Maria Grossrubatscher, Elia Guadagno, Concetta Sciammarella, Antongiulio Faggiano, Annamaria Al Colao
The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking advantage of the most modern techniques, in the perspective of personalized medicine and appropriate resource utilization. This review summarizes the available data on the possible role of circulating tumor cells and microRNAs as prognostic markers in NENs...
April 7, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28389503/the-purine-receptor-p2x7r-regulates-release-of-pro-inflammatory-cytokines-in-human-craniopharyngioma
#10
Jing Nie, Guanglong Huang, Shengze Deng, Yun Bao, Yawei Liu, Zhanpeng Feng, Chaohu Wang, Ming Chen, Songtao Qi, Jun Pan
Craniopharyngiomas (CPs) are usually benign, non-metastasizing embryonic malformations originating from the sellar area. They are, however, locally invasive and generate adherent interfaces with the surrounding brain parenchyma. Previous studies have shown the tumor microenvironment is characterized by a local abundance of Adenosine Triphosphate (ATP), infiltration of leukocytes, and elevated levels of pro-inflammatory cytokines that are thought to be responsible, at least in part, for the local invasion. Here we examine whether ATP, via the P2X7R, participates in the regulation of cytokine expression in CPs...
April 7, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28351943/apc-but-not-obesity-synergizes-with-pten-to-drive-intestinal-stem-cell-tumors
#11
Tahmineh Tabrizian, Donghai Wang, Fangxia Guan, Zunju Hu, Amanda Beck, Fabien Delahaye, Derek M Huffman
Obesity is a major risk factor for colorectal cancer and can accelerate Lgr5+ intestinal stem cell (ISC)-derived tumorigenesis following inactivation of Apc. However, whether non-canonical pathways involving PI3K-Akt signaling in ISCs can lead to tumor formation, and if this can be further exacerbated by obesity is unknown. Despite the synergy between Pten and Apc inactivation in epithelial cells on intestinal tumor formation, their combined role in Lgr5+-ISCs, which are the most rapidly dividing ISC population in the intestine, is unknown...
March 28, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28351942/targeting-the-tsh-receptor-in-thyroid-cancer
#12
Christopher W Rowe, Jonathan Paul, Craig Gedye, Jorge Tolosa, Cino Bendinelli, Shaun McGrath, Roger Smith
Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients...
March 28, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28341725/paraneoplastic-endocrine-syndromes
#13
Georgios K Dimitriadis, Anna Angelousi, Martin O Weickert, Harpal S Randeva, Gregory A Kaltsas, Ashley B Grossman
The majority of neoplasms produce symptoms related to mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin...
March 24, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#14
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28289080/microrna-applications-for-prostate-ovarian-and-breast-cancer-in-the-era-of-precision-medicine
#15
Bethany Smith, Priyanka Agarwal, Neil A Bhowmick
The high degree of conservation in microRNA from Caenorhabditis elegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microRNA to address these changes holds significant promise. However, prostate, ovarian, and breast cancers are heterogeneous and face issues of evolving therapeutic resistance. Transforming growth factor-beta (TGF-ß) signaling axis plays an important role in the progression of each of these cancers, in part through microRNA regulation, and reciprocally, microRNA regulation of TGF-ß actions...
March 13, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28274953/incidence-of-malignant-tumours-in-patients-with-a-non-functioning-pituitary-adenoma
#16
Daniel S Olsson, Casper Hammarstrand, Ing-Liss Bryngelsson, Anna G Nilsson, Eva Andersson, Gudmundur Johannsson, Oskar Ragnarsson
Whether patients with non-functioning pituitary adenoma (NFPA) are at increased risk of developing malignant tumours has been sparsely studied and is a matter of debate. In this study, we have investigated the incidence of malignant tumours in a large and unselected group of patients with NFPA. The study was nationwide and included all patients diagnosed with NFPA between 1987-2011 (n=2,795) in Sweden, identified in the National Patient Register. Malignant tumours, occurring after the NFPA diagnosis, were identified in the Swedish Cancer Register between 1987-2014...
March 8, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28270435/timing-of-multikinase-inhibitor-initiation-in-differentiated-thyroid-cancer
#17
Marcia S Brose, Jan Wa Smit, Chia-Chi Lin, Fabian Pitoia, Marc Fellous, Yoriko DeSanctis, Martin Schlumberger, Masayuki Tori, Iwao Sugitani
There are limited treatment options for patients with radioactive iodine-refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients with radioactive iodine -refractory, progressive differentiated thyroid cancer for whom there is a decision to initiate multikinase inhibitors at study entry (cohort 1) with those for whom there is a decision to not initiate multikinase inhibitors at study entry (cohort 2)...
March 7, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249964/minimal-extrathyroidal-extension-does-not-affect-survival-of-well-differentiated-thyroid-cancer
#18
Zaid Al-Qurayshi, Mohamed Ahmed Shama, Gregory W Randolph, Emad Kandil
Differentiated thyroid cancer (DTC) with minimal extrathyroidal extension (MEE), is classified as stage III regardless of the tumor size. In this study, we aim to examine the effect of MEE on the overall survival and management of this population. Using a retrospective cohort study utilizing the National Cancer Data Base (NCDB), 2004-2012, the study population included patients, ≥ 45 years old, who underwent surgery for DTC (pT3N0M0) with MEE compared to patients with (pT2N0M0). We found a total of 9556 patients were included...
March 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249963/cell-death-response-to-anti-mitotic-drug-treatment-in-cell-culture-mouse-tumor-model-and-the-clinic
#19
Jue Shi, Timothy J Mitchison
Anti-mitotic cancer drugs include classic microtubule-targeting drugs, such as taxanes and vinca alkaloids, and the newer spindle-targeting drugs, such as inhibitors of the motor protein, Kinesin-5 (aka KSP, Eg5, KIF11), and Aurora-A, Aurora-B and Polo-like kinases. Microtubule-targeting drugs are among the first line of chemotherapies for a wide spectrum of cancers, but patient responses vary greatly. We still lack understanding of how these drugs achieve a favorable therapeutic index, and why individual patient responses vary...
March 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28249962/local-optometrists-are-a-major-source-of-referrals-to-a-pituitary-tumour-clinic
#20
Haval Surchi, Bahram Jafar-Mohammadi, Aparna Pal, Simon Cudlip, Ashley B Grossman
Pituitary adenomas can be identified pathologically in some 20-25% of autopsy specimens, but only around 1/1000 of the population have clinically significant tumours.Classic bitemporal hemianopia occurs as tumour expands. These visual symptoms are the most common objective manifestations of non-functioning pituitary adenomas, and demand urgent decompression to increase the probability of a complete normalisation of visual function. Delayed diagnosis may lead to irreversible visual loss.The onset of the visual deficit is usually gradual such that many patients might not seek medical consultation for months or even years...
March 1, 2017: Endocrine-related Cancer
journal
journal
32030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"